Analysis of the efficacy of ruxolitinib cream (Opzelura) in treating vitiligo and patients’ real experience

Ruxolitinib cream (Opzelura) is a topical medication used primarily to treat adults and adolescents with localized vitiligo. Its mechanism of action reduces the local immune response in the skin by inhibiting the Janus kinase (JAK) signaling pathway, thereby promoting the recovery of melanocyte function. Clinical trials have shown that patients who use ruxolitinib cream to treat vitiligo have significant pigment regeneration in some skin lesions after several weeks of continuous use, especially in patients with small lesions on the face and hands. The effect is more significant.

In actual patient experience, some patients may experience slight stinging or itching at the beginning of use, but this usually gradually eases as the medication is prolonged. Most patients report that after continuous use for 8 to 12 weeks, the skin color gradually becomes even and the pigment recovery effect can last for several months. For patients with early-stage vitiligo and localized vitiligo, the efficacy of ruxolitinib cream is more prominent, while the recovery speed of large-area or advanced vitiligo is relatively slow.

It is worth noting that ruxolitinib cream is a topical drug. Patients need to apply it strictly in accordance with the doctor's instructions and avoid excessive use or simultaneous use of other irritating drugs to reduce the risk of local skin adverse reactions. At the same time, attention should be paid to sun protection and skin moisturizing during treatment to assist the drug in exerting its best effect. Patient feedback shows that rational use of medication combined with daily care can significantly improve the effect of pigment recovery.

Overall, ruxolitinib cream shows good efficacy and tolerability in the treatment of vitiligo, and is especially suitable for patients with localized and early-stage vitiligo. Patients should remain patient during use, follow up regularly to evaluate the treatment effect, and combine it with daily care measures to obtain sustained and stable pigment recovery effects. At the same time, clinicians can individually adjust the medication frequency and course of treatment according to the location and area of u200bu200bthe patient's skin lesions to optimize the treatment plan.

Reference materials:https://www.drugs.com/